Loading…
S. 1414119th CongressPlaced on the calendarLatest action Jul 27, 2026Decoded by AI · checked against the record
Official title: Expedited Access to Biosimilars Act
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
S 1414 would let biosimilar makers skip certain clinical studies unless the FDA specifically requires them in advance.
45-second read · 4 questions answered below
The bill would end the automatic requirement for immunogenicity, pharmacodynamics, and comparative efficacy studies for biosimilar drug approval. Companies would instead only need to show safety and expected results in one approved use through simpler pharmacokinetic testing. The FDA could still require the extra studies case by case, but only with early written notice explaining why.
This mainly affects pharmaceutical companies developing biosimilar drugs, which are cheaper alternatives to complex biologic medicines used for conditions like arthritis, cancer, or diabetes. Patients and doctors could also be affected through changes in access to and confidence in these drugs.
Fewer required studies could shorten approval timelines and lower development costs for biosimilar makers, while raising questions for some about whether reduced testing affects confidence in drug safety or effectiveness. The change would apply only to applications submitted after the law takes effect.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it was placed on the Senate floor calendar, and the official record shows no floor action on it since. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.